A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

← catalyst calendar

NCT06297590 · readout ≤ 193 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Basic science

Enrollment

48estimated

Sites

Countries

Japan, United Kingdom, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-08-15

actual

When the study began enrolling

Primary completion

Feb 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Feb 2027

estimated

The whole study's end, after follow-up

First posted

2024-03-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Alzheimer Disease

Interventions

Drug: LY3954068
Drug: Placebo
Drug: Flortaucipir F18

Primary outcomes

what the primary-completion date above is the date OF

Part A: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration

measured Baseline up to Week 24 and Week 72 (for optional bridging period participants)

Part B: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration

measured Baseline up to Week 52

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed